There is an opening at EORTC Headquarters in Brussels for a Medical Vice Director
Posted on 22 December 2011
The ideal candidate for this position would be an oncologist and/or hematologist with strong leadership skills, experience in clinical research, and well recognized in the international academic and pharmaceutical industry sectors. Read more
Dr. Yan Liu recently joined EORTC Headquarters as a fellow in the Translational Research, Radiotherapy, and Imaging Department
Posted on 22 December 2011
Dr. Yan Liu completed her medical studies at the Shanghai Jiaotong University College of Medicine in Shanghai, China, where she also received her Master of Medicine in Image Diagnosis. Following her medical studies she spent two years as a resident radiologist in the imaging diagnosis center at the Shanghai Children’s Medical Center. Read more
EORTC members to receive free eBook access to Touch Briefings
Posted on 22 December 2011
As part of a Media partnership with Touch Briefings, EORTC members receive free eBook access to Touch Briefings ‘EU Oncology and Haematology’ Volume 7 Issue 3
European Oncology & Haematology is a peer-reviewed quarterly journal that includes review articles, case reports, practice guidelines and original research. Guided by an Editorial Board of world-renowned physicians, European Oncology & Haematology comprises articles from recognised thought leaders to provide concise and timely update on the latest opinion and advances spanning the breadth of oncology and haematology practice. Read more
New EORTC studies opened in 2011
Posted on 22 December 2011
Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. Read more
The NCI Cancer Prevention Fellowship Program will again host the NCI Summer Curriculum in Cancer Prevention in 2012
Posted on 22 December 2011
This educational opportunity has long been recognized as an opportunity for scientists, clinicians, and persons from other disciplines to learn the latest information about preventing cancer.
Excellence in Oncology 2012 to be organized under the auspices of the EORTC
Posted on 22 December 2011
22-25 February 2012, Istanbul, Turkey
Introducing EiO 2012 - The second in a series of annual international conferences in the field of oncology featuring distinguished experts selectively presenting the latest scientific findings and advances in oncology, as these relate to clinical practice. Read more
International Rare Cancer Initiative EORTC – UK – US Global Collaboration
Posted on 23 November 2011
The EORTC has joined forces with Cancer Research UK, the National Institute for Health Research Cancer Research Network (NCRN), and the United States National Cancer Institute (NCI) to launch an initiative to boost the development of new treatments for patients with rare cancers. Read more
EORTC, BIG, and Agendia Announce: Completion of Patient Recruitment for International MINDACT Study
Posted on 18 October 2011
Brussels, Belgium, IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, 18 October 2011 – The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than 6,600 patients in 111 institutions across nine countries were enrolled from February 2007 to July 2011 in this trial. Read more
Choice of antiepileptic drug for brain tumor patients may affect survival
Posted on 12 October 2011
New research suggests brain tumor patients who take the antiepileptic drug valproic acid on top of standard treatment may live a few months longer than people who take other kinds of epilepsy medications to control seizures. The research is published in the 31 August 2011 online issue of Neurology®, the medical journal of the American Academy of Neurology. Read more
Three chemotherapy regimens shown to be active against extensive disease small cell lung cancer in EORTC trial 08062
Posted on 12 October 2011
Small cell lung cancer (SCLC) accounts for approximately one fifth of all lung carcinomas, and chemotherapy remains the preferred treatment for patients with this disease. Chemotherapy regimens for SCLC have included many different compounds, cyclophosphamide, doxorubicin, methotrexate, etoposide, vincristine, cisplatin and carboplatin to name a few, but the standard treatment is a doublet of cisplatin or carboplatin with etoposide. Read more